Pfizer acquires Metsera in $10 billion deal after competitive bidding with Novo Nordisk

Core Viewpoint - Pfizer Inc. has agreed to acquire Metsera Inc. for $10 billion, following a competitive bidding process with Novo Nordisk A/S [1][2] Group 1: Acquisition Details - Pfizer will pay up to $86.25 per share for Metsera, which includes an initial cash payment of $65.60 per share and potential milestone payments of up to $20.65 per share [1] - The new bid from Pfizer is 5 cents per share higher than its previous offer, indicating a strategic move to secure the acquisition [2] Group 2: Competitive Landscape - The acquisition announcement positions Pfizer favorably in the bidding competition against Novo Nordisk, highlighting the competitive nature of the weight-loss drug market [2] - Metsera's board has stated that the Pfizer bid represents "the best transaction for shareholders," reflecting confidence in the deal's value [2]